瘤抗原呈现和相关的信号转导在致癌过程中
Sohom Naskar1, Nawaneetan Sriraman1, Ankita Sarkar1
1Department of Biotechnology, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India.
Pathology, research and practice
|August 1, 2024
概括
癌症突变可以通过改变主要基因相容综合体 (MHC) 受体来逃避免疫检测. 本综述探讨了PI3K通路,MHC变化以及树突细胞在癌症生存中的作用.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 癌症是一种复杂的疾病,有100多种类型,由遗传,环境和行为因素驱动.
- DNA中的突变是癌症发展的关键,影响瘤基因,瘤抑制剂和免疫信号通路.
- 癌细胞可以通过降低主要基因相容性复合体 (MHC) 类I和II受体的调节来逃避免疫监测,从而阻碍T细胞的识别.
研究的目的:
- 审查PI3K途径在癌症发展和向治疗中的作用.
- 检查MHC类I和II表达的变化及其对患者生存的影响.
- 探索瘤微环境中的树突细胞 (DCs) 的参与.
主要方法:
- 文献综述侧重于PI3K通路信号传递,MHC改变和癌症中的树突细胞功能.
- 分析癌细胞逃避免疫检测的机制.
- 讨论治疗挑战和抵抗途径.
主要成果:
- PI3K通路的激活,通常与mTOR相关,在癌症中至关重要.
- 降低MHC I和MHC II的调节是一种常见的免疫逃避策略.
- 与瘤相关的MHCII类 (tsMHC-II) 表达与无疾病和整体存活率呈正相关性.
结论:
- 了解PI3K通路和MHC调节对于开发有效的癌症治疗非常重要.
- 状细胞在瘤微环境中起着复杂的作用.
- 耐药性机制,包括RAS介导的瘤发生和PI3K信号传递,存在重大治疗障碍.
相关概念视频
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)

